A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Clinical trial NCT00695396 · TERMINATED

Trial details

NCT number: NCT00695396
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Anemia

Start date: 2008-06-01
Primary completion: 2010-01-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.